tagraxofusp-erzs (elzonris) Report issue

Active Ingredient History

NOW
  • Now
Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018, and after a second review, in the EU in January 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.   Wikipedia

More Chemistry
  • Mechanism of Action:
  • Multi-specific: No
  • Payload: diphtheria toxin
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Drug Pricing (per unit)

United States

$18319.8800
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

sl-401 | tagraxofusp-erzs

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue